Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms

Journal of Immunology

Volumn 166, Issue 3, 2001, Pages 1921-1929

  Streit, J A ^a   Recker, T J ^a   Gueiros Filho, F ^a   Beverley, S M ^a   Wilson, M E ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLIC ACID; EPITOPE; GAMMA INTERFERON; THYMIDYLATE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNITY; INFECTION SENSITIVITY; LEISHMANIA CHAGASI; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; MOUSE; NATURAL KILLER CELL; NONHUMAN; PARASITE VIRULENCE; PRIORITY JOURNAL; PROMASTIGOTE; SKIN INFECTION; VISCERAL LEISHMANIASIS;

EID: 0035253505     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.3.1921     Document Type: Article

References (65)

1. Leishmaniasis
2. A prospective study of visceral leishmaniasis in an endemic area of Brazil
3. Reciprocal expression of interferon-γ or interleukin 4 during the resolution or progression of murine leishmaniasis
4. + lymphocytes in vivo during healing and progressive murine leishmaniasis
5. Immuno-regulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens
6. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice
7. Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type I immune response
8. + T cell subsets and induces early resistance to Leishmania major in mice
9. Two types of mouse T helper cell clones IV: Th2 clones secrete a factor that inhibits cytokine production by Th1 clones
10. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody: Evidence for a T cell-dependent, interferon-γ-independent mechanism
11. Local suppression of IFN-γ in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi
12. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis
13. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major
14. Experimental cutaneous leishmaniasis: Effects of thymectomy on the course of infection of CBA mice with Leishmania tropica
15. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis
16. Expression cloning of a protective Leishmania antigen
17. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection
18. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12
19. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multi-copy gene family
20. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
21. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major
22. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection
23. Effective immunization against cutaneous leishmaniasis with recombinant Bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63
24. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis
25. Development of a safe live Leishmania vaccine line by gene replacement
26. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major
27. Leishmania major: Effect of infectious dose on T cell subset development in BALB/c mice
28. Mechanism of lethal effect of human serum upon Leishmania donovani
29. Identification of an infective stage of Leishmania promastigotes
30. Genes selectively expressed in the infectious (metacyclic) stage of Leishmania major promastigotes encode a potential basic-zipper structural motif
31. Shuttle cosmid vectors for the trypanosomatid parasite Leishmania
32. Double targeted gene replacement for creating null mutants
33. Expression of the major surface glycoprotein of Leishmania donovani chagasi in virulent and attenuated promastigotes
34. Selection against the dihydrofolate reductase-thymidylate synthase (DHFR-TS) locus as a probe of genetic alterations in Leishmania major
35. Gene replacement in parasitic protozoa
36. Host resistance to the Khartoum strain of Leishmania donovani
37. Standardization of the chromium-51, cell-mediated cytotoxicity assay: Cryopreservation of mouse effector and target cells
38. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani
39. The importance of transforming growth factor-β in murine visceral leishmaniasis
40. Developmentally regulated expression of a novel 59-kDa product of the major surface protease (Msp or gp63) gene family of Leishmania chagasi
41. Glycoprotein 46 mRNA abundance is post-transcriptionally regulated during development of Leishmania chagasi promastigotes to an infectious form
42. Experimental leishmaniasis in humans
43. Heterologous protection by Leishmania donovani for Leishmania major infections in the verbet monkey model of disease
44. Murine cutaneous leishmaniasis: Disease patterns in intact and nude mice of various genotypes and examination of some differences between normal and infected macrophages
45. Nature of resistance to leishmaniasis in experimental rodents
46. Rate of Leishmania-induced skin lesion development in rodents depends on the site of inoculation
47. + T cells through IL-12 produced by Listeria-induced macrophages
48. IFN-γ modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis
49. In vivo effects of anti-asialo GM1: Reduction of NK activity and enhancement of transplanted tumor growth in nude mice
50. A glycolipid on the surface of mouse natural killer cells
51. + cells
52. Modulation of macrophage function by transforming growth factor-β, interleukin-4, and interleukin-10
53. Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor-β1 null mouse
54. Transforming growth factor-β in leishmanial infection: A parasite escape mechanism
55. Clinical spectrum of leishmaniasis
56. Bumps on the vaccine road
57. Immunological regulation of experimental cutaneous leishmaniasis: Nature and significance of specific suppression of cell-mediated immunity in mice highly susceptible to Leishmania tropica
58. Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically susceptible BALB/c mice
59. Recombinant interleukin 12 cures mice infected with Leishmania major
60. Resistance to Leishmania major induced by tolerance to a single antigen
61. Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei: Implications for enzyme turnover and selective difluoromethylornithine inhibition
62. Site-specific immunity to Leishmania major in SWR mice: The site of infection influences susceptibility and expression of the antileishmanial immune response
63. Mechanisms of immunity to leishmaniasis. IV. Significance of lymphatic drainage from the site of infection
64. Evolution of the genus Leishmania as revealed by comparisons of nuclear DNA restriction fragment patterns